Plasma circulating tumour DNA is a better source for diagnosis and mutational analysis of IVLBCL than tissue DNA
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18576 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Chao Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Mutation, Lymphoma, Large B-Cell, Diffuse, Biomarkers, Tumor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding, Capital's Funds for Health Improvement and Research.
Abstract (Originalsprache)
Diagnosis of intravascular large B‐cell lymphoma (IVLBCL) is a challenge due to its heterogeneous clinical presentation and lack of specific markers. This retrospective study investigated the utility of circulating tumour DNA (ctDNA) sequencing for diagnosing IVLBCL and analysing its mutation landscape. A cohort of 34 IVLBCL patients enrolled and underwent plasma ctDNA targeted sequencing. The median plasma ctDNA concentration was 135.0 ng/mL, significantly higher than that in diffuse large B‐cell lymphoma (DLBCL) controls. Correlations were found between ctDNA concentration and disease severity indicators, LDH and SF. Mutation analysis revealed frequent mutations in B‐cell receptor and NF‐κB signalling pathways, including MYD88 (56%), CD79B (44%), TNFAIP3 (38%) and IRF4 (29%). CNS involvement was significantly related with BCL6 and CD58 mutation. Patients with complicated hemophagocytic lymphohistiocytosis had significantly higher mutation rates in B2M . Comparison with DLBCL subtypes showed distinctive mutation profiles in IVLBCL. Moreover, plasma ctDNA detected more mutations with higher variant allele fraction than tissue DNA, suggesting its superiority in sensitivity and accessibility. Dynamic monitoring of ctDNA during treatment correlated with therapeutic responses. This study revealed the role of ctDNA in IVLBCL diagnosis, mutation analysis, and treatment monitoring, offering a promising avenue for improving patient diagnosis in this rare lymphoma subtype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Chao Chen, Zhe Zhuang, Wei Wang, Chong Wei, Yan Zhang
Förderung
- National High Level Hospital Clinical Research Funding
- Capital's Funds for Health Improvement and Research
Zitieren
APA
Chen, C., Di, Y., Zhuang, Z., Cai, H., Jia, C., Wang, W., Zhao, D., Wei, C., Zhang, W., Zhou, D., & Zhang, Y. (2024). Plasma circulating tumour DNA is a better source for diagnosis and mutational analysis of IVLBCL than tissue DNA. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18576
Vancouver
Chen C, Di Y, Zhuang Z, Cai H, Jia C, Wang W, et al. Plasma circulating tumour DNA is a better source for diagnosis and mutational analysis of IVLBCL than tissue DNA. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18576
BibTeX
@article{Chen2024,
author = {Chen, Chao and Di, Yiao and Zhuang, Zhe and Cai, Hao and Jia, Congwei and Wang, Wei and Zhao, Danqing and Wei, Chong and Zhang, Wei and Zhou, Daobin and Zhang, Yan},
title = {Plasma circulating tumour DNA is a better source for diagnosis and mutational analysis of IVLBCL than tissue DNA},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18576}
}
EUVIMED